Key result
Transseptal MyVal balloon-expandable valve implantation succeeds in 1 patient with a failed surgical mitral bioprosthesis.
Case Report (n=1)
This case report demonstrates the feasibility of using the novel MyVal balloon-expandable device for transcatheter mitral valve-in-valve replacement in a failed surgical bioprosthesis.
Answers are grounded in this paper and cite their sources.
Does not support routine use; leaves open safety and efficacy of MyVal for mitral valve-in-valve replacement.
We describe a patient with symptomatic severe mitral regurgitation, due to a failed 33-mm Epic (St. Jude Medical, St. Paul, MN) bioprosthetic heart valve surgically implanted 10-year before. For this specific purpose, we implanted a novel balloon-expandable transcatheter heart valve, the MyVal (Meril Life Science, Vapi, India). To the best of our knowledge, this is the second case describing the implantation of MyVal in a degenerative, surgically placed bioprosthesis.
No takes yet. Share an insight, caveat, or question.
Drakopoulou et al. (2022) conducted a case report in Symptomatic severe mitral regurgitation (n=1). MyVal balloon-expandable transcatheter heart valve was evaluated. A novel balloon-expandable transcatheter heart valve (MyVal) was implanted in 1 patient with severe mitral regurgitation due to a failed surgical bioprosthesis.
Synapse has enriched 10 related papers. Consider them for comparative context: